Viruses for tumor therapy

John Bell, Douglas McFadden

Research output: Contribution to journalShort survey

58 Citations (Scopus)

Abstract

Oncolytic virotherapy exploits live viruses with selective tropism for cancerous cells and tissues to treat cancer. As discussed here, the field has progressed considerably as a result of both the successes and failures of previous and on-going clinical trials for various cancers. These studies indicate that oncolytic viruses are remarkably safe and more efficacious when virus replication stimulates sustained antitumor immune responses. In the future, virotherapy should be combined with immunomodulatory reagents that target immune tolerance to established cancers.

Original languageEnglish (US)
Pages (from-to)260-265
Number of pages6
JournalCell Host and Microbe
Volume15
Issue number3
DOIs
StatePublished - Mar 12 2014
Externally publishedYes

Fingerprint

Oncogenic Viruses
Oncolytic Virotherapy
Oncolytic Viruses
Neoplasms
Immune Tolerance
Tropism
Virus Replication
Therapeutics
Clinical Trials
Viruses

ASJC Scopus subject areas

  • Parasitology
  • Microbiology
  • Virology

Cite this

Viruses for tumor therapy. / Bell, John; McFadden, Douglas.

In: Cell Host and Microbe, Vol. 15, No. 3, 12.03.2014, p. 260-265.

Research output: Contribution to journalShort survey

Bell, John ; McFadden, Douglas. / Viruses for tumor therapy. In: Cell Host and Microbe. 2014 ; Vol. 15, No. 3. pp. 260-265.
@article{edc86bc3be394ad8924b983d7d2e1830,
title = "Viruses for tumor therapy",
abstract = "Oncolytic virotherapy exploits live viruses with selective tropism for cancerous cells and tissues to treat cancer. As discussed here, the field has progressed considerably as a result of both the successes and failures of previous and on-going clinical trials for various cancers. These studies indicate that oncolytic viruses are remarkably safe and more efficacious when virus replication stimulates sustained antitumor immune responses. In the future, virotherapy should be combined with immunomodulatory reagents that target immune tolerance to established cancers.",
author = "John Bell and Douglas McFadden",
year = "2014",
month = "3",
day = "12",
doi = "10.1016/j.chom.2014.01.002",
language = "English (US)",
volume = "15",
pages = "260--265",
journal = "Cell Host and Microbe",
issn = "1931-3128",
publisher = "Cell Press",
number = "3",

}

TY - JOUR

T1 - Viruses for tumor therapy

AU - Bell, John

AU - McFadden, Douglas

PY - 2014/3/12

Y1 - 2014/3/12

N2 - Oncolytic virotherapy exploits live viruses with selective tropism for cancerous cells and tissues to treat cancer. As discussed here, the field has progressed considerably as a result of both the successes and failures of previous and on-going clinical trials for various cancers. These studies indicate that oncolytic viruses are remarkably safe and more efficacious when virus replication stimulates sustained antitumor immune responses. In the future, virotherapy should be combined with immunomodulatory reagents that target immune tolerance to established cancers.

AB - Oncolytic virotherapy exploits live viruses with selective tropism for cancerous cells and tissues to treat cancer. As discussed here, the field has progressed considerably as a result of both the successes and failures of previous and on-going clinical trials for various cancers. These studies indicate that oncolytic viruses are remarkably safe and more efficacious when virus replication stimulates sustained antitumor immune responses. In the future, virotherapy should be combined with immunomodulatory reagents that target immune tolerance to established cancers.

UR - http://www.scopus.com/inward/record.url?scp=84896087235&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84896087235&partnerID=8YFLogxK

U2 - 10.1016/j.chom.2014.01.002

DO - 10.1016/j.chom.2014.01.002

M3 - Short survey

VL - 15

SP - 260

EP - 265

JO - Cell Host and Microbe

JF - Cell Host and Microbe

SN - 1931-3128

IS - 3

ER -